NCT02340208 - A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 1, 2017

Study Completion Date

December 20, 2017

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

L-DOS47

A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.

Trial Locations (5)

Mazovian Center of Pulmonary Diseases and Tuberculosis, Otwock

Med. Polonia Hospital Poznan, Poznan

Institute of Tuberculosis and Lung Diseases, Warsaw

Military Medical Institute, Warsaw

The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, Warsaw